ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,057.60
-0.02%
다우존스 지수
38,686.32
1.51%
Bitcoin
67,483.00
-1.29%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Orchard Therapeutics PLC (ORTX)

  7. Orchard Therapeutics PLC (ORTX) 뉴스

ORTX

Orchard Therapeutics (ORTX)

Orchard Therapeutics PLC
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ORTX
일자시간출처헤드라인심볼기업
2024/05/0720:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024NASDAQ:ORTXOrchard Therapeutics PLC
2024/05/0320:00GlobeNewswire Inc.Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListNASDAQ:ORTXOrchard Therapeutics PLC
2024/03/2020:00GlobeNewswire Inc.Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyNASDAQ:ORTXOrchard Therapeutics PLC
2024/03/1904:41GlobeNewswire Inc.Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.NASDAQ:ORTXOrchard Therapeutics PLC
2024/02/1511:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORTXOrchard Therapeutics PLC
2024/02/0604:39Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ORTXOrchard Therapeutics PLC
2024/02/0521:00GlobeNewswire Inc.Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeNASDAQ:ORTXOrchard Therapeutics PLC
2024/02/0221:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/3114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/3114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2521:00GlobeNewswire Inc.Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2507:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2507:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2507:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:37Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:35Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:34Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:30Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:25Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2506:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2419:00GlobeNewswire Inc.Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesNASDAQ:ORTXOrchard Therapeutics PLC
2024/01/2306:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
2023/12/2006:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
2023/12/1121:00GlobeNewswire Inc.Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDNASDAQ:ORTXOrchard Therapeutics PLC
2023/12/0906:39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
2023/12/0906:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
2023/12/0106:13Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
 검색 관련기사 보기:NASDAQ:ORTX

최근 히스토리

AMEX
SPY
SPDR S&P 500
COIN
SOLUSD
Solana
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
NYSE
JPM
JP Morgan Chase
PM
XAUUSD
Gold vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
NYSE
XOM
Exxon Mobil
USOTC
RHHBY
Roche (QX)
COIN
BTCUSD
Bitcoin
AMEX
XLF
Financial Select Sector
USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
NYSE
CVX
Chevron
CCOM
US100
US Tech 100
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유